Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.80 |
| ▸ | PDE2A | O00408 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | NT5E | P21589 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | CD99 | P14209 | 1/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897823 | 1.00 | ADORA2A (0.80) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL5709816 | 1.00 | ADORA2A (0.80) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL12667516 | 1.00 | ADORA2A (0.80) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL29403114 | 1.00 | ADORA2A (0.80) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL12223712 | 1.00 | ADORA2A (0.80) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL1897825 | 1.00 | ADORA2A (0.80) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL24233629 | 1.00 | ADORA2A (0.80) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL15544938 | 1.00 | ADORA2A (0.80) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL24233566 | 0.90 | ADORA3 (0.68) | ADORA2AADORA3ADORA1PDE2AADRA1A | |
| SCHEMBL24233601 | 0.90 | ADORA3 (0.68) | ADORA2AADORA3ADORA1PDE2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033432-A1 | ANTI-HEPATITIS B VIRUS AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110118339-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118339-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS (US) | 2011-03-17 | — | — | US | disclosed |
| WO-2010101951-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2009099942-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009099942-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009091982-A1 | MIR-122 AGONIST | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091972-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091982-A1 | MIR-122 AGONIST | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091972-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| EP-1395266-A1 | ANTIVIRAL NUCLEOSIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-10 | — | — | EP | disclosed |
| US-6660721-B2 | Treatment or prophylaxis of hepatitis C virus infections; viricides | HOFFMANN-LA ROCHE INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030083307-A1 | Anti-HCV nucleoside derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-05-01 | — | — | US | disclosed |
| WO-2002094289-A1 | ANTIVIRAL NUCLEOSIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | AGO2, BCDIN3D, TRDMT1 | ADORA2A 2390/4885ADORA3 1677/4885ADORA1 2942/4885 |
| US-20030083307-A1 | Anti-HCV nucleoside derivatives | HAVCR2, EIF2AK2, NSUN2 | ADORA2A 167/4885ADORA3 120/4885ADORA1 310/4885 |
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | DCLRE1B, RNGTT, NSUN2 | ADORA2A 755/4885ADORA3 1023/4885ADORA1 1943/4885 |
| US-20220033432-A1 | ANTI-HEPATITIS B VIRUS AGENT | SLC10A1, HAVCR2, FABP1 | ADORA2A 1834/4885ADORA3 1331/4885ADORA1 801/4885 |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | NSUN2, RNMT, RNGTT | ADORA2A 354/4885ADORA3 499/4885ADORA1 766/4885 |
| US-20110118339-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | TRDMT1, NSUN3, BCDIN3D | ADORA2A 957/4885ADORA3 745/4885ADORA1 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.